Adocia Cash Flow Conversion Efficiency
Adocia cash flow conversion efficiency. Based on the latest financial reports, Adocia (ADOC) has a cash flow conversion efficiency ratio of 1.826x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.72 Million ≈ $3.18 Million USD) by net assets (€1.49 Million ≈ $1.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Adocia (2010–2025)
Cash flow conversion efficiency of Adocia from 2010 to 2025. This chart illustrates how Adocia's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Adocia for real-time trading data and today's change.
Adocia Cash Flow Conversion Ratio Explained
Adocia cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Adocia Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adocia ranked by their cash flow conversion efficiency. Also see ADOC market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spirax Group plc
LSE:SPX
|
0.053x |
|
Champions Oncology Inc
NASDAQ:CSBR
|
-0.306x |
|
Groupe LDLC SA
PA:ALLDL
|
-0.164x |
|
DCC plc
LSE:DCC
|
0.011x |
|
Taekyung BK Co Ltd
KO:014580
|
0.037x |
|
Deneb Investments Ltd
JSE:DNB
|
0.147x |
|
Coffee Day Enterprises Limited
NSE:COFFEEDAY
|
0.025x |
|
Susco Public Company Limited
BK:SUSCO
|
0.112x |
Annual Cash Flow Conversion Efficiency for Adocia (2010–2025)
The table below shows the annual cash flow conversion efficiency of Adocia from 2010 to 2025. Review ADOC cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.49 Million ≈ $1.74 Million |
€-6.53 Million ≈ $-7.63 Million |
-4.380x | -186.66% |
| 2024-12-31 | €-3.09 Million ≈ $-3.61 Million |
€-15.61 Million ≈ $-18.25 Million |
5.054x | +605.94% |
| 2023-12-31 | €-6.91 Million ≈ $-8.08 Million |
€-4.95 Million ≈ $-5.79 Million |
0.716x | -38.08% |
| 2022-12-31 | €-12.97 Million ≈ $-15.16 Million |
€-14.99 Million ≈ $-17.53 Million |
1.156x | -16.95% |
| 2021-12-31 | €-13.81 Million ≈ $-16.15 Million |
€-19.23 Million ≈ $-22.49 Million |
1.392x | +140.35% |
| 2020-12-31 | €6.33 Million ≈ $7.41 Million |
€-21.85 Million ≈ $-25.55 Million |
-3.450x | -902.03% |
| 2019-12-31 | €28.04 Million ≈ $32.78 Million |
€-9.65 Million ≈ $-11.29 Million |
-0.344x | -350.07% |
| 2018-12-31 | €45.85 Million ≈ $53.60 Million |
€6.31 Million ≈ $7.38 Million |
0.138x | +122.83% |
| 2017-12-31 | €36.86 Million ≈ $43.09 Million |
€-22.23 Million ≈ $-25.99 Million |
-0.603x | -96.29% |
| 2016-12-31 | €42.76 Million ≈ $49.99 Million |
€-13.14 Million ≈ $-15.36 Million |
-0.307x | -132.56% |
| 2015-12-31 | €47.05 Million ≈ $55.01 Million |
€-6.22 Million ≈ $-7.27 Million |
-0.132x | -101.08% |
| 2014-12-31 | €2.50 Million ≈ $2.93 Million |
€30.56 Million ≈ $35.73 Million |
12.200x | +2261.78% |
| 2013-12-31 | €19.13 Million ≈ $22.36 Million |
€-10.80 Million ≈ $-12.62 Million |
-0.564x | -1514.13% |
| 2012-12-31 | €23.03 Million ≈ $26.92 Million |
€919.00K ≈ $1.07 Million |
0.040x | +102.78% |
| 2011-12-31 | €4.33 Million ≈ $5.06 Million |
€-6.22 Million ≈ $-7.27 Million |
-1.436x | -209.61% |
| 2010-12-31 | €10.69 Million ≈ $12.49 Million |
€-4.96 Million ≈ $-5.79 Million |
-0.464x | -- |
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more